Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

被引：0
|
作者：
Nicola Ferrante
Daniela Ritrovato
Rossella Bitonti
Gianluca Furneri
机构：
[1] Novartis Farma S.p.A,
[2] EBMA Consulting,undefined
来源：
BMC Health Services Research | / 22卷
关键词：
Brolucizumab; Neovascular age-related macular degeneration; nAMD; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
    Ferrante, Nicola
    Ritrovato, Daniela
    Bitonti, Rossella
    Furneri, Gianluca
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [2] Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
    Yu, Justin S.
    Carlton, Rashad
    Agashivala, Neetu
    Hassan, Tarek
    Wykoff, Charles C.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (06): : 743 - 752
  • [3] The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
    Musial-Kopiejka, Magdalena
    Polanowska, Katarzyna
    Dobrowolski, Dariusz
    Krysik, Katarzyna
    Wylegala, Edward
    Grabarek, Beniamin Oskar
    Lyssek-Boron, Anita
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (04)
  • [4] COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN GREECE
    Kourlaba, G.
    Tzanetakos, C.
    Datseris, J.
    Rouvas, A.
    Arzoumanidou, D.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A421 - A421
  • [5] NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) IN ITALY: A SOCIAL COST ANALYSIS
    Fasci, A.
    Pradelli, L.
    VALUE IN HEALTH, 2022, 25 (12) : S261 - S261
  • [6] Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial
    Dugel, Pravin U.
    Jaffe, Glenn J.
    Sallstig, Peter
    Warburton, James
    Weichselberger, Andreas
    Wieland, Mark
    Singerman, Lawrence
    OPHTHALMOLOGY, 2017, 124 (09) : 1296 - 1304
  • [7] COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN SWEDEN
    Clements, K. M.
    Hulbert, E. M.
    Panchmatia, H. R.
    Eriksson, M.
    Wittrup-Jensen, K. U.
    Nilsson, J.
    Weinstein, M. C.
    VALUE IN HEALTH, 2013, 16 (07) : A506 - A506
  • [8] Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration
    Hikaru Ota
    Jun Takeuchi
    Yuyako Nakano
    Etsuyo Horiguchi
    Yosuke Taki
    Yasuki Ito
    Hiroko Terasaki
    Koji M. Nishiguchi
    Keiko Kataoka
    Japanese Journal of Ophthalmology, 2022, 66 : 278 - 284
  • [9] Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration
    Ota, Hikaru
    Takeuchi, Jun
    Nakano, Yuyako
    Horiguchi, Etsuyo
    Taki, Yosuke
    Ito, Yasuki
    Terasaki, Hiroko
    Nishiguchi, Koji M.
    Kataoka, Keiko
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2022, 66 (03) : 278 - 284
  • [10] Brolucizumab Use in Treatment Resistant Neovascular Age Related Macular Degeneration (nAMD)
    Shortell, Justin
    Hill, Christine
    Thomas, Claire
    Peck, Travis
    Melamud, Alexander
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
12345